Comindus Finance Form 4 KYTO BIOPHARMA / GEORGES BENARROCH ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

COMINDUS FINANCE CORP.

(Last) (First) (Middle)

134 DUKE DRIVE

(Street)

LAKE WORTH FL 33460

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KYTO BIOPHARMA INC [ KBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common	02/21/2018		J		958,752(1)	A	$1.13	2,697,085	D
Common	02/21/2018		J		958,752(2)(3)	D	$1.13	2,697,085	I	Owner of Comindus Finance Corp.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

COMINDUS FINANCE CORP.

(Last) (First) (Middle)

134 DUKE DRIVE

(Street)

LAKE WORTH FL 33460

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

BENARROCH GEORGES

(Last) (First) (Middle)

78 HAZELTON AVENUE

(Street)

TORONTO A6 M5R2E2

(City) (State) (Zip)

Explanation of Responses:

1. This is to report the sale of 958,752 common shares owned by Georges Benarroch to Comindus Finance Corp. and the pledge of 958,752 by Comindus Finance Corp. to Georges Benarroch until such time as the full purchase price has been paid.

2. -Georges Benarroch, President and Director of the Issuer, is an officer and director of Comindus Finance Corp. and responsible for day to day operations. He is the beneficial owner in securities held by Comindus Finance Corp.

3. Form 4 Joint Filer Information: Georges Benarroch Address: 78 Hazelton Avenue, Toronto ON M5R2E2 Canada Designated Filer Comindus Finance Corp. Issuer and Ticker Symbol: Kyto BioPharma Inc. (KBPH) Date of Event Requiring Statement: February 21, 2018 Relationship of Reporting Person to Issuer: Director, Officer, President Signature /s/ Georges Benarroch

	Georges Benarroch President	02/21/2018
	Georges Benarroch	02/21/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.